miR-301a expression: Diagnostic and prognostic marker for prostate cancer

This study establishes the role of microRNA 301a (miR-301a) as a supplemental biomarker that can distinguish between patients with benign prostate hyperplasia and clinically significant CaP. We evaluate the ability of miR-301a to predict the adverse pathology of CaP.

Source: Urologic Oncology: Seminars and Original Investigations - September 5, 2018 Category: Urology & Nephrology Authors: Venkatesh Kolluru, Balaji Chandrasekaran, Ashish Tyagi, Adnan Dervishi, Murali Ankem, Xiaofang Yan, Kong Maiying, Houda Alatassi, Saad P. Shaheen, Ahmed Haddad, Chendil Damodaran, Jamie C. Messer, Angelena Edwards Tags: Original Article Source Type: research